{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:40:43Z","timestamp":1793421643129,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-154294"],"award-info":[{"award-number":["FDN-154294"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA043526"],"award-info":[{"award-number":["DA043526"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neuropharm.2025.110698","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:26:13Z","timestamp":1758630373000},"page":"110698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluating the reinforcing properties of oxycodone and oxymorphone using intravenous drug self-administration in male rats"],"prefix":"10.1016","volume":"281","author":[{"given":"Mina","family":"Rashvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9508-3354","authenticated-orcid":false,"given":"Douglas","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-2280","authenticated-orcid":false,"given":"Paul J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-3745","authenticated-orcid":false,"given":"Sharon","family":"Miksys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110698_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/0091-3057(79)90175-8","article-title":"Rapid substitution procedure for intravenous drug self-administration studies in rhesus monkeys","volume":"10","author":"Aigner","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110698_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114949","article-title":"Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia","volume":"198","author":"Arguelles","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-021-05872-1","article-title":"Relative potency of intravenous oxymorphone compared to other \u03bc opioid agonists in humans \u2014 pilot study outcomes","volume":"238","author":"Babalonis","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12173","article-title":"Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans","volume":"21","author":"Babalonis","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-023-03583-0","article-title":"Active uptake of oxycodone at both the blood-cerebrospinal fluid barrier and the blood-brain barrier without sex differences: a rat microdialysis study","volume":"40","author":"B\u00e4llgren","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2025.110698_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)24040-X","article-title":"The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley\/dark agouti rat model","volume":"271","author":"Cleary","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110698_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1301479","article-title":"Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers","volume":"33","author":"Comer","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110698_bib8","article-title":"Reporting animal research: explanation and elaboration for the arrive guidelines 2.0","author":"du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward","author":"Fields","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110698_bib10","series-title":"Current Medical Research and Opinion","article-title":"Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study","author":"Gabrail","year":"2004"},{"key":"10.1016\/j.neuropharm.2025.110698_bib11","article-title":"The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain","volume":"99","author":"Gimbel","year":"2004","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2025.110698_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2023.1143373","article-title":"Effects of sex and estrous cycle on intravenous oxycodone self-administration and the reinstatement of oxycodone-seeking behavior in rats","volume":"17","author":"Hinds","year":"2023","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110698_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-024-00532-w","article-title":"Regulation of brain fluid volumes and pressures: basic principles, intracranial hypertension, ventriculomegaly and hydrocephalus","author":"Hladky","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neuropharm.2025.110698_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1127735","article-title":"Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats","volume":"14","author":"Illenberger","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1915143117","article-title":"Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats","volume":"117","author":"Kallupi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110698_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpainsymman.2005.01.010","article-title":"Oxycodone","author":"Kalso","year":"2005","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.neuropharm.2025.110698_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high \u2018liking\u2019, \u2018wanting\u2019, and abuse liability","author":"Kibaly","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/00000542-200610000-00027","article-title":"Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats","volume":"105","author":"Lemberg","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2025.110698_bib19","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.1987.253.2.E228","article-title":"A microdialysis method allowing characterization of intercellular water space in humans","volume":"253","author":"Lonnroth","year":"1987","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2025.110698_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-017-4536-6","article-title":"Oxycodone self-administration in male and female rats","volume":"234","author":"Mavrikaki","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12590","article-title":"Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia","volume":"24","author":"McMillan","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib22","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.105.094276","article-title":"Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female sprague-dawley rats","volume":"316","author":"Peckham","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110698_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"Poyhia","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110698_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","author":"Richardson","year":"1996","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2025.110698_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)33473-7","article-title":"A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion","volume":"224","author":"Risner","year":"1983","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110698_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/BF02246019","article-title":"Parametric analysis of cocaine self-administration under a progressive-ratio schedule in rhesus monkeys","volume":"125","author":"Rowlett","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jps.23492","article-title":"Oxymorphone active uptake at the blood-brain barrier and population modeling of its pharmacokinetic-pharmacodynamic relationship","volume":"102","author":"Sadiq","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110698_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1301454","article-title":"Nicotine self-administration, extinction responding and reinstatement in adolescent and adult male rats: evidence against a biological vulnerability to nicotine addiction during adolescence","volume":"33","author":"Shram","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110698_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s002130050702","article-title":"Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review","author":"Stafford","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-021-05808-9","article-title":"The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization","volume":"238","author":"Stocco","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib31","series-title":"Current Protocols in Neuroscience","article-title":"Chronic intravenous drug self-administration in rats and mice","author":"Thomsen","year":"2005"},{"key":"10.1016\/j.neuropharm.2025.110698_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-33458-8","article-title":"Ketogenic diet enhances the effects of oxycodone in mice","volume":"13","author":"Trinko","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110698_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110698_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin-\u03ba opioid system in the reinforcing effects of drugs of abuse","author":"Wee","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110698_bib35","article-title":"Mu opioid receptor\u2013expressing neurons in the dorsal raphe nucleus are involved in reward processing and affective behaviors","volume":"94","author":"Welsch","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110698_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46111-1","article-title":"Voluntary alcohol intake alters the motivation to seek intravenous oxycodone and neuronal activation during the reinstatement of oxycodone and sucrose seeking","volume":"13","author":"Wilkinson","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110698_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-018-0284-5","article-title":"Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects","volume":"44","author":"You","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110698_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000103923","article-title":"Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests","volume":"80","author":"Zernig","year":"2007","journal-title":"Pharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500406X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500406X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:39:08Z","timestamp":1773124748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500406X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S002839082500406X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110698","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the reinforcing properties of oxycodone and oxymorphone using intravenous drug self-administration in male rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110698"}}